Always putting healthier
lives first
scroll
News
-
Sawai Group Reports Third Quarter FY2023 Financial Results
-
Integrated Report 2023 has been released
-
Sawai Group Holdings Announces Change of Representative Directors and Corporate Officers
-
Sawai Group Reports First Half of Quarter FY2022 Financial Results
-
Sawai Group Reports First Quarter FY2022 Financial Results
-
Sawai Receives Approvals for Three Generic Drugs with Four Strengths
-
Notice of Transfer (Sale of Shares/Equity Interests) of Sawai’s U.S. Subsidiary / Sub-subsidiary
-
Sawai Announces Listing of a single Generic Drug with Two Strengths
-
Launch of Pitavastatin tablets in the United States – Sawai’s First generic ANDA approval and launch for US market under Paragraph IV–
-
Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP
Company Information
Group Companies
